Literature DB >> 19449129

First case report of Muir-Torre syndrome associated with non-small cell lung cancer.

L Nolan1, D Eccles, E Cross, G Crawford, N Beck, A Bateman, C Ottensmeier.   

Abstract

The eponymous Muir-Torre syndrome (MTS) is a clinical variant of hereditary non polyposis colorectal cancer, and is defined as an autosomal dominant condition with simultaneous sebaceous neoplasms of the skin and visceral malignant disease resulting from germline mutations in the DNA mismatch repair (MMR) genes. To date the most common visceral malignancy described is colorectal cancer, which is seen in approximately 50% of cases. Other clearly associated tumours include endometrial adenocarcinomas, urothelial transitional cell carcinomas, upper gastrointestinal adenocarcinomas, sebaceous adenomas and ovarian (often mucinous) carcinomas. Here we report the first recorded case of adenocarcinoma of the lung with loss of MMR gene function to be identified in a patient with MTS. The MMR deficient lung tumour demonstrated less aggressive clinical behaviour compared with a synchronous MMR proficient lung adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19449129     DOI: 10.1007/s10689-009-9247-7

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  23 in total

1.  Cancer family "G" revisited: 1895-1970.

Authors:  H T Lynch; A J Krush
Journal:  Cancer       Date:  1971-06       Impact factor: 6.860

2.  Multiple sebaceous tumors.

Authors:  D Torre
Journal:  Arch Dermatol       Date:  1968-11

3.  Multiple sebaceous gland tumours, with multiple tumours of internal organs. A new syndrome?

Authors:  P M Bakker; S S Tjon A Joe
Journal:  Dermatologica       Date:  1971

4.  Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face.

Authors:  E G Muir; A J Bell; K A Barlow
Journal:  Br J Surg       Date:  1967-03       Impact factor: 6.939

5.  The Muir-Torre syndrome: a rare variant of hereditary nonpolyposis colorectal cancer associated with hMSH2 mutation.

Authors:  A Suspiro; P Fidalgo; M Cravo; C Albuquerque; E Ramalho; C N Leitão; F Costa Mira
Journal:  Am J Gastroenterol       Date:  1998-09       Impact factor: 10.864

Review 6.  Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review.

Authors:  H T Lynch; T C Smyrk; P Watson; S J Lanspa; J F Lynch; P M Lynch; R J Cavalieri; C R Boland
Journal:  Gastroenterology       Date:  1993-05       Impact factor: 22.682

7.  The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer.

Authors:  R Fishel; M K Lescoe; M R Rao; N G Copeland; N A Jenkins; J Garber; M Kane; R Kolodner
Journal:  Cell       Date:  1993-12-03       Impact factor: 41.582

8.  [Sebaceous hyperplasias, kerato-acanthomas, epitheliomas of the face and cancer of the colon. A new entity?].

Authors:  J Reiffers; P Laugier; N Hunziker
Journal:  Dermatologica       Date:  1976

9.  Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer.

Authors:  F S Leach; N C Nicolaides; N Papadopoulos; B Liu; J Jen; R Parsons; P Peltomäki; P Sistonen; L A Aaltonen; M Nyström-Lahti
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

10.  Non-Hodgkin lymphoma related to hereditary nonpolyposis colorectal cancer in a patient with a novel heterozygous complex deletion in the MSH2 gene.

Authors:  M Pineda; E Castellsagué; E Musulén; G Llort; T Frebourg; S Baert-Desurmont; S González; G Capellá; I Blanco
Journal:  Genes Chromosomes Cancer       Date:  2008-04       Impact factor: 5.006

View more
  8 in total

Review 1.  Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry.

Authors:  Jinru Shia; Susanne Holck; Giovanni Depetris; Joel K Greenson; David S Klimstra
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

Review 2.  Germline mutations predisposing to non-small cell lung cancer.

Authors:  Gerald H Clamon; Aaron D Bossler; Taher Abu Hejleh; Muhammad Furqan
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

3.  Long-Lasting Response to Nivolumab for a Patient With Lynch Syndrome-Associated Lung Adenocarcinoma.

Authors:  Keita Masuzawa; Takanori Asakura; Shinnosuke Ikemura; Hiroyuki Yasuda; Ichiro Kawada; Sosuke Takaoka; Yuichiro Hayashi; Takeshi Nakajima; Masami Arai; Koichi Fukunaga; Kenzo Soejima
Journal:  JCO Precis Oncol       Date:  2020-02-14

4.  Primary sclerosing epithelioid fibrosarcoma of the lung in a patient with Lynch syndrome.

Authors:  Priska Leisibach; Walter Weder; Alex Soltermann; Wolfgang Jungraithmayr
Journal:  Lung       Date:  2012-07-06       Impact factor: 2.584

Review 5.  Cervical neuroendocrine tumor in a young female with Lynch Syndrome.

Authors:  Ibraheem Yousef; Fadi Siyam; Lester Layfield; Carl Freter; James R Sowers
Journal:  Neuro Endocrinol Lett       Date:  2014       Impact factor: 0.765

6.  Pulmonary sclerosing hemangioma in a 21-year-old male with metastatic hereditary non-polyposis colorectal cancer: report of a case.

Authors:  Tobias S Schiergens; Philipe N Khalil; Doris Mayr; Wolfgang E Thasler; Martin K Angele; Rudolf A Hatz; Karl-Walter Jauch; Axel Kleespies
Journal:  World J Surg Oncol       Date:  2011-06-06       Impact factor: 2.754

7.  Towards gene- and gender-based risk estimates in Lynch syndrome; age-specific incidences for 13 extra-colorectal cancer types.

Authors:  Christina Therkildsen; Steen Ladelund; Lars Smith-Hansen; Lars Joachim Lindberg; Mef Nilbert
Journal:  Br J Cancer       Date:  2017-10-24       Impact factor: 7.640

8.  Case Report and Literature Review: Diagnosis, Tailored Genetic Counseling and Cancer Prevention for a Locally Advanced dMMR/MSI-H/TMB-H Lung Cancer Patient With Concurrent Lynch Syndrome Mediated by a Rare PMS2 Splicing Variant (c.1144+1G>A).

Authors:  Quanli Han; Si Liu; Zhi Cui; Qi Wang; Tonghui Ma; Liwen Jiang; Xiaomo Li; Guanghai Dai
Journal:  Front Genet       Date:  2022-01-18       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.